--News Direct--
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic compound found in certain types of mushrooms.
The company will work in partnership with other pharmaceutical companies to determine the best potential use for psilocybin.
Clements says that "the focus of MGC will not change" despite the news, adding that it is fully committed to its current pipeline of products.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/mgc-pharmaceuticals-focus-will-not-change-despite-psilocybin-news-998844428
